Pigging Can Improve Efficiency and Sustainability - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pigging Can Improve Efficiency and Sustainability


Equipment and Processing Report

Untitled Document

As pharmaceutical manufacturers strive to find green production methods, many companies are discovering that sustainable strategies also can improve efficiency and reduce costs. One such strategy is pigging, the process of injecting a sanitary, solid, silicone rubber projectile into a safe, closed-loop sanitary system to clean out the pipeline between batches (see Figure 1). The projectile, or pig, is forced through a pipeline by compressed air, carbon dioxide, nitrogen, water, or the next product. The pigs generally are made of medical-grade silicone that complies with 21 CFR Section 177.2600 and is approved by the US Food and Drug Administration.

Fig 1 A pig made of silicone rubber.
Figure 1: A pig made of silicone rubber. Image is courtesy of Process Pigging Systems.

A unit called a pig detector helps ensure that a pig is not lost. A pig detector also automates the pigging system so that operators can send it back and forth in a pipeline accurately (see Figure 2). Some of pigging’s advantages for the pharmaceutical processing industry include the following:

  • Product recovery higher than 99%
  • Quick product changeovers
  • A 50% reduction in water consumption
  • A 30% reduction in cleaning-chemical consumption.

Product recovery

Because they rely on expensive ingredients and manufacture valuable finished products, pharmaceutical processors have long sought ways to increase product recovery. Companies typically have addressed the problem by limiting the size of their pipelines because small pipelines are easier to clean than large ones.

Fig 2 A Pig detector, sensor, and pipeline bracket.
Figure 2: A Pig detector, sensor, and pipeline bracket. Image is courtesy of Process Pigging Systems.

But manufacturers do not have to limit pipeline size, which can also reduce productivity. Introducing a sanitary pig into a pipeline effectively pushes usable material into a filler, storage tank, tanker, or a final package for product recovery. Operators also can clean challenging areas such as 90° elbows fully with a pig. Pigging can recover product at a rate higher than 99%. As the value of the recovered product increases, the time required to achieve a return on the investment in the pigging system is shortened.

As more material is recovered and converted into finished product, the scrap volume is decreased, and batch yields rise. Pigging technology is equally effective on pipelines with large diameters, thus pharmaceutical manufacturers can achieve significant increases in production by using 2-in. pipelines rather than the 1-in. models that are currently the standard. Pigs are available in sizes from 0.5 to 8 in.

Improved product recovery increases efficiency, lowers the cost of individual items, and increases a production line’s profitability. A reduction in the scrap rate translates directly into decreased waste-handling and -hauling fees. If scrap liquid product is discharged into the sewer, a lower scrap rate can mean reduced surcharges, especially for high biochemical-oxygen-demand materials.

Product changeover

Many of the pharmaceutical industry’s processes rely on batch manufacturing and produce several batches per day or shift. Time is valuable in such a production environment. Because batch-to-batch consistency and cleanliness are vitally important, the cleaning process must be rigorous. A long cleaning cycle—including a water flush, the introduction of clean-in-place (CIP) chemicals, and another water flush—usually is necessary.

Injecting a sanitary pig into the pipeline, however, can eliminate the need for the initial water flush and the time associated with it. Because pigging cleans the pipeline so effectively, it reduces cross-contamination concerns and quickens the cleaning process. The pig’s effectiveness comes from the fact that it is slightly oversized and pushes out the product like a squeegee.

Pigging typically reduces cleaning cycle time by half, thus enabling more batches to be produced with the same equipment per day or per shift. When pipelines with large diameters are used, these production increases and efficiency gains are compounded. Pigging systems can be used before cleaning validation or integrated into cleaning-validation procedures.

Reduced water and chemical use

For companies that are looking for ways to reduce their environmental footprint, pigging could be a way to reduce water consumption because it eliminates the need for an initial water flush during CIP. The technique could be especially valuable in areas that experience drought conditions.

Companies that switched from traditional CIP systems to pigging systems have reported a water savings of roughly 50% and a chemical savings of about 30%. This reduced use of resources not only saves the cost of water itself, but also the cost of water treatment and sewerage costs. Depending upon the particular circumstances of a production line, this saving can improve the return on the investment in the pigging system.

Reduced cycle times, reduced water and chemical consumption, and greatly increased product recovery and production rates are important reasons that pharmaceutical manufacturers are becoming interested in pigging. This technology helps pharmaceutical manufactures establish sustainable processes on the plant floor and can help them improve their bottom lines.

Neil O’Connor is president of Process Pigging Systems, 1776 Mentor Ave., Cincinnati, OH 45212, tel. 513.731.6005, neiloconnor@processpigging.com, www.ProcessPigging.com.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Equipment and Processing Report,
Click here